Chemical structure of thyroxine
Find information on thousands of medical conditions and prescription drugs.

Liothyronine Sodium

The thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are tyrosine-based hormones produced by the thyroid gland. An important component in the synthesis is iodine. The major form of thyroid hormone in the blood is thyroxine (T4). This is converted to the active T3 within cells by deiodinases. These are further processed by decarboxylation and deiodination to produce iodothyronamine (T1a) and thyronamine (T0a). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Circulation

Most of the thyroid hormone circulating in the blood is bound to transport proteins :

  • Thyroxine-binding globulin (TBG)
  • Thyroid-binding prealbumin (TBPA) - this protein is also responsible for the transport of retinol, and so now has the preferred name of transthyretin (TTR)
  • albumin.

Only a very small fraction of the circulating hormone is free (unbound) - T4 0.03% and T3 0.3%. This free fraction is biologically active, hence measuring concentrations of free thyroid hormones is of great diagnostic value. These values are referred to as fT4 and fT3. Another critical diagnostic tool is the amount of thyroid-stimulating hormone that is present. When thyroid hormone is bound, it is not active, so the amount of free T3/T4 is what is important. For this reason, measuring total thyroxine in the blood can be misleading.

Function

The thyronines act on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline).The thyroid hormones are essential to proper development and differentiation of all cells of the human body. To various extents, they regulate protein, fat and carbohydrate metabolism. But they have their most pronounced effects on how human cells use energetic compounds. Numerous physiological and pathological stimuli influence thyroid hormone synthesis.

The thyronamines function via some unknown mechanism to inhbit neuronal activity; this plays an important role in the hibernation cycles of mammals. One effect of administering the thyronamines is a severe drop in body temperature.

Related diseases

Both excess and deficiency of thyroxine can cause disorders.

  • Thyrotoxicosis or hyperthyroidism is the clinical syndrome caused by an excess of circulating free thyroxine, free triiodothyronine, or both. It is a common disorder that affects approximately 2% of women and 0.2% of men.
  • Hypothyroidism is the case where there is a deficiency of thyroxine.

Medical use of thyroid hormones

Both T3 and T4 are used to treat thyroid hormone deficiency (hypothyroidism). They are both absorbed well by the gut, so can be given orally. Levothyroxine, the most commonly used form, is a stereoisomer of physiological thyroxine, which is metabolised more slowly and hence usually only needs once-daily administration.

Thyronamines have no medical usages yet, though their use has been proposed for controlled induction of hypothermia which causes the brain to enter a protective cycle, useful in preventing damage during ischemic shock.

Read more at Wikipedia.org


[List your site here Free!]


How should thyroid replacement be initiated?
From Journal of Family Practice, 11/1/04 by Suzanne E. Landis

* EVIDENCE-BASED ANSWER

Levothyroxine (LT4) should be used alone as initial replacement for patients with hypothyroidism (strength of recommendation [SOR]: A). The optimal initial dose is 1.6 [micro]g/kg/d for healthy people aged 60 years or younger (SOR: B). Patients aged more than 60 years may require less levothyroxine to achieve therapeutic serum thyroid hormone replacement, so initial replacement should be decreased to 25 to 50 [micro]g daily (SOR: C).

Since patients with known heart disease may develop dysrhythmias, angina, and myocardial infarctions when started on full replacement doses, experts recommend starting 12.5 to 25 [micro]g daily for this population (SOR: C). Brand-name (Synthroid, Levoxyl, etc) and generic LT4 are bioequivalent (SOR: B), although the US Food and Drug Administration (FDA) does not consider these products to be interchangeable until proven therapeutically equivalent.

* EVIDENCE SUMMARY

Initial thyroid replacement with synthetic LT4 is recommended because LT4 is safe, effective, reliably relieves symptoms, and normalizes lab tests for hypothyroid patients. (1,2)

Two recent randomized trials comparing LT4 alone or LT4 and LT3 together for a total of 86 adult hypothyroid patients found similar outcomes. One study, which enrolled patients with hypothyroidism and mild depressive symptoms, assessed scores on the Symptom Check-List-90, the Comprehensive Epidemiological Screens for Depression, and the Medical Outcomes Study health status questionnaire at baseline and multiple times over the duration of the study. For these outcomes, no differences were found between the LT4 alone and combination LT4-LT3 treatment groups within 90% confidence intervals. (3) A second study assessed changes in body weight, lipid profile, hypothyroid-specific health-related quality-of-life scores, and 13 neuropsychological measures pre- and posttreatment. This study detected no difference in body weight and serum lipids at baseline and after treatment. The hypothyroid-specific health-related quality-of-life scores similarly improved for both treatment groups. Twelve of 13 neuropsychological tests demonstrated no differences between treatment groups; the Grooved Peg Board Test of manual dexterity and fine visual-motor coordination demonstrated a slight improvement for the LT4 alone treatment group. (4)

The initial dose of LT4 can be based on the age and health status of the patient. The mean replacement dose of LT4 is 1.6 [micro]g/kg/d for healthy patients aged [less than or equal to] 60 years. (5-7) Patients aged >60 years should be started on 25 to 50 [micro]g daily. An uncontrolled cohort study of 84 patients found that for patients aged >60 years, 25- to 50-[micro]g doses of LT4 resulted in similar serum thyrotropin (TSH) levels as the higher (1.6 [micro]g/kg/d) doses required for younger patients. (7) Based on expert opinion, patients of any age with heart disease should be given lower doses of 12.5 to 25 [micro]g daily as initial treatment. (1,2))

The choice of the LT4 preparation continues to be debated. In 1997, a bioequivalence study compared 2 generic brands to 2 name brands by having 22 women with hypothyroidism, who were euthyroid on replacement medication, take each preparation for 6 weeks. (8) The area under the curve, peak serum concentration, and time to peak concentration for 3 indexes of thyroid function (thyroxine, triiodothyronine, and free T4 index) were not significantly different and met the FDA criterion for relative bioequivalence. However, they did not examine therapeutic equivalence and from a clinical perspective, some researchers and pharmaceutical companies felt that the authors could not comment on whether the products were interchangeable. (8,9) The FDA now requires thyroxine bioavailability and bioequivalence studies to evaluate product substitution. (10) The FDA lists Levothyroxine Sodium (Mylan) to be therapeutically equivalent and therefore interchangeable with Unithroid. (11)

* RECOMMENDATIONS FROM OTHERS

The American Association of Clinical Endocrinologists Thyroid Task Force recommends the use of a high-quality brand preparation of LT4 rather than desiccated thyroid hormone, combinations of thyroid hormones, or LT3. (12) It recommends a mean replacement dosage of LT4 of 1.6 [micro]g/kg of body weight per day with initial dose ranging from 12.5 [micro]g daily to a full replacement dosage based on the age, weight, and cardiac status of the patient.

UpToDate states that although LT4 products are standardized, subtle differences between preparations exist, and products should be interchanged only with sufficient monitoring after the change. In addition, they recommend generally avoiding generics because the pharmacy may interchange products without physicians being aware. (1) The Physicians' Information and Education Resource from the American College of Physicians states "Name-brand LT4 products provide more consistent potency than generic preparations. The cost of brand-name LT4 products is only slightly more than that of generic preparations." (2)

REFERENCES

(1.) Ross DS. Treatment of hypothyroidism. UpToDate. Last update January 9, 2004. Available at: www.uptodate.com. Accessed on March 4, 2004.

(2.) McDermott MT. Hypothyroidism. ACP's PIER: Physicians' Information and Education Resource. Last update March 17, 2004. Available at: http://online, statref.com/document.aspx?fxid=50&docid=1297. Accessed on May 10, 2004.

(3.) Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88:4551-4555.

(4.) Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290:2952-2958.

(5.) Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316:764-770.

(6.) Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325-333.

(7.) Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Aging and the thyroid: Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983; 75:206-209.

(8.) Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997; 277:1205-1213.

(9.) Rennie D. Thyroid storm. JAMA 1997; 277:1238-1243.

(10.) Hennessey JV. Precise thyroxine dosing: Clinical requirements. Endocrinologist 2003; 13:479-487.

(11.) FDA Center for Drug Evaluation and Research. Drugs@FDA: Levothyroxine Sodium (Genetic Drug). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on June 3, 2004.

* CLINICAL COMMENTARY

Instruct patients about the timing of levothyroxine and potential interactions

The starting dose of levothyroxine for hypothyroid patients is based on age, severity of the disease, duration of the disease, and existing comorbid conditions. For healthy adults 60 years of age or younger, the optimal starting dose is 1.6 [micro]g/kg/d. For patients more than 60 years of age, the initial dose is 25 to 50 [micro]g/d. To avoid cardiac complications among persons with known heart disease, the recommended initial levothyroxine dose is 12.5 [micro]g/d. In my experience, these guidelines work well in initiating treatment for hypothyroidism.

Few of my patients have noted any difference between generic and brand-name thyroid supplements. Knowing what other medications the patient is taking is important, since medications such as estrogen can decrease the bioavailability of levothyroxine by increasing binding proteins. It is also important to instruct patients about the timing of levothyroxine intake, because some medications can affect absorption (eg, cholestyramine, calcium, or iron).

Santhi Penmetsa, MD, Department of Family and Community Medicine, Baylor College of Medicine

Suzanne E. Landis, MD, MPH, University of North Carolina at Chapel Hill, Mountain Area Health Education Center, Asheville, NC; Linda J. Collins, MSLS, University of North Carolina at Chapel Hill

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Liothyronine Sodium
Home Contact Resources Exchange Links ebay